Novartis, Eli Lilly marquee positive survival data for CDK 4/6 franchises — but can they actually beat Pfizer's blockbuster?
BARCELONA — A little more than a year after Pfizer’s big CDK 4/6 cancer drug blockbuster Ibrance failed to hit the mark in overall survival …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
